Utah Clinical Trials Report — May 2026

For Utah residents considering participation in clinical research, May 2026 presents a crucial period, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 66 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 4 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on specific types of cancer, neurological disorders, and cardiovascular health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder
• Advanced breast cancer
• Acute lymphoblastic leukemia
• Advanced solid tumor
• Aortic insufficiency
• Advance directives
• Advance care planning
• Acute undifferentiated leukemia
• Advanced NSCLC
• ALS - Amyotrophic Lateral Sclerosis

Major Research Initiatives Launch in Utah

This month brings several high-profile new trials to Utah, including significant Phase 2 and 3 studies from major pharmaceutical companies and leading academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to pain management and mental health.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• Rebel Medicine Inc is leading NCT07574385, a Phase 2 study named "Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy." This trial will involve 60 participants and evaluates the safety, pharmacokinetics, efficacy, and pharmacodynamics of ALX006, an extended-release bupivacaine formulation, administered as a single-dose sciatic nerve block in adults undergoing bunionectomy.
• Irma Fleming is sponsoring NCT07563296, a Phase 2 study titled "KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury." This innovative study will enroll 12 participants to look at the safety and tolerability of KAP (Ketamine-Assisted Psychotherapy) in the burn population, specifically addressing PTSD and trauma-related symptoms.

Utah's Evolving Research Landscape

This month, Utah saw the opening of 6 new clinical trials, a notable decrease compared to the 22 trials that launched in March 2026. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 1,168 clinical trials currently recruiting across 44 cities and 516 research sites.

The majority of new research initiatives this month are concentrated in the Salt Lake City metropolitan area, with 4 of the 6 new trials opening in Salt Lake City itself. Other cities across the state also saw new trial launches, including Millcreek, Murray, Sandy City, and South Jordan, each with 1 new trial. This indicates a continued focus on urban centers for new research, while overall trial availability remains widespread.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Obesity
• Cognitive ability, general
• Emotions
• Hallux valgus
• Heart failure
• Immune system function
• Post-transplant lymphoproliferative disorder
• PTSD and trauma-related symptoms
• Bunionectomy
• Type 2 diabetes

The types of interventions being studied are varied, with drug trials leading the way, accounting for 5 of the new trials. Other new studies include behavioral interventions, dietary supplements, and procedures.

Diverse Participation: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 6 new trials launched this month, 5 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is open to children, offering opportunities for younger participants to engage in research that could benefit their age group.

For individuals without a specific medical condition, there are significant opportunities to contribute. 1 of the new trials this month is actively seeking healthy volunteers. Across Utah, a total of 93 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions continue to play a vital role in Utah's research ecosystem, with the University of Utah sponsoring 2 of the new trials. Industry sponsors, including Novo Nordisk A/S and Rebel Medicine Inc, are also driving significant research efforts, accounting for 3 of the new studies this month. The remaining 3 new trials are sponsored by other organizations, including Irma Fleming.

As we move through May, the focus will likely shift towards the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Utah.